124 results on '"Weinberg, Benjamin Adam"'
Search Results
2. Real-world microscopic residual disease (MRD) monitoring with circulating tumor DNA (ctDNA) in pancreatic adenocarcinoma (PDAC).
3. Clinical and molecular characterization of FAP and SPP1 in colorectal cancer (CRC), CALGB (Alliance)/SWOG 80405 and real-world data.
4. Investigating the clinical and molecular characteristics of class II and III BRAF mutations and their response to anti-EGFR therapy in MSS CRC: A comprehensive analysis.
5. Phase II trial of BXCL701 and pembrolizumab in patients with metastatic pancreatic ductal adenocarcinoma (EXPEL-PANC): Preliminary findings.
6. Uncovering actionable genetic alterations and immune predictive biomarkers for anal squamous cell carcinomas in the era of immunotherapy: PD-L1 and beyond.
7. Characterization of necroptosis activators in colorectal cancer.
8. Identification and characterization of immunogenic neoantigens in colorectal cancer (CRC).
9. Identification and characterization of immunogenic neoantigens in biliary cancer (BC) and pancreatic cancer (PC).
10. Association of class II and III BRAF mutations with EGFR blockade therapy response and representation of molecularly distinct subgroups of BRAF mutations in MMR proficient CRC.
11. Genomic analysis of oesophageal carcinoma (EC) to identify recurrent mutations in histone methyltransferases as a distinctive subset.
12. Impact of next-generation sequencing in biliary tract cancer treatment.
13. Molecular differences with therapeutic implications in early-onset compared to average-onset cholangiocarcinoma.
14. Molecular and immune landscape by cyclin dependent kinase (CDK) 4/6 expression and TP53 mutational status in mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) colorectal cancer (CRC).
15. Evaluating novel therapies and circulating tumor DNA (ctDNA) as a marker of response in curatively treated gastrointestinal cancers with microscopic residual disease.
16. Characterization of the cachexia pathway in pancreatic ductal adenocarcinoma.
17. LMTK3 gene expression and the molecular landscape of colorectal cancer (CRC).
18. Genomics and transcriptomics of pancreatic adenosquamous carcinoma.
19. Changes in circulating immune biomarkers following nivolumab with or without ipilimumab for metastatic anal cancer (NCI9673).
20. A phase I dose escalation study of eryaspase in combination with modified FOLFIRINOX in locally advanced and metastatic pancreatic ductal adenocarcinoma.
21. Microscopic residual disease (MRD) monitoring with circulating tumor DNA (ctDNA) across gastrointestinal (GI) malignancies.
22. The role of gene expression of CDC37 in colorectal cancer (CRC).
23. Continuous maintenance (Maint) capecitabine (Cape) dosing for colorectal (CRC) and pancreatic cancers (PC): A single-institution, retrospective, real-world study.
24. Tissue factor expression in colorectal cancer.
25. Phase I study of proton therapy in adjuvant pancreatic cancer (PROTON-PANC).
26. Analysis of HLA gene expression in patients with dMMR/MSI-H colorectal carcinoma resistant to immune checkpoint inhibitors.
27. Molecular correlates of DSCR1 expression in colorectal cancer (CRC).
28. Beyond CPS for PD-L1 scoring: Genetic alterations that impact efficacy of immunotherapy in hepatocellular carcinoma (HCC).
29. Comparative analyses of intratumoral microbiome with diet in patients with early- vs late-onset colorectal cancer.
30. Success rates and clinicopathologic associations with experimental outcomes of a novel circulating tumor cell (CTC) technology in advanced colon cancer (CC) and pancreatic cancer (PC).
31. SETD2 gene expression and the molecular landscape of colorectal cancer (CRC).
32. Comparative analysis of the molecular profile and tumor immune microenvironment (TIME) of human epidermal growth factor receptor 2 (HER2) low (L)- versus high (H)-expressing gastroesophageal cancers (GEC).
33. Landscape of endocytosis pathway in colorectal cancer (CRC).
34. CXCR4 overexpression: An indicator of poor survival and predictor of response to immunotherapy in patients with metastatic colorectal cancer.
35. Comprehensive profiling of clock genes expression in colorectal cancer (CRC).
36. Comprehensive characterization of PTPRT expression in colorectal cancer (CRC).
37. Characterization of NY-ESO-1 gene expression in gastric cancer (GC).
38. Characterization of TIM3 and its ligands in colorectal cancer.
39. DEFB1 gene expression and the molecular landscape of colorectal cancer (CRC).
40. Interim safety and efficacy results from a phase 1 study of NT219 in adults with advanced solid tumors.
41. Updated clinical outcomes from ULI-EAP-100, an intermediate expanded access program for ulixertinib (BVD-523).
42. Claudin 18 (CLDN18) gene expression and related molecular profile in gastric cancer (GC).
43. Efficacy and safety of zenocutuzumab, a HER2 x HER3 bispecific antibody, across advanced NRG1 fusion (NRG1+) cancers.
44. Molecular correlates of MAEA expression in colorectal cancer (CRC).
45. Outcomes in patients undergoing curative surgery for gastric cancer by facility type and socioeconomic factors: An analysis of the National Cancer Database (NCDB).
46. REVERCEII (ACCRU-GI-1809): A randomized phase II study of regorafenib followed by anti-EGFR monoclonal antibody therapy versus the reverse sequencing for metastatic colorectal cancer patients previously treated with fluoropyrimidine, oxaliplatin and irinotecan.
47. A phase I dose-escalation study of eryaspase in combination with modified FOLFIRINOX in locally advanced and metastatic pancreatic ductal adenocarcinoma: Interim update.
48. Prognostic utility of preoperative and postoperative circulating tumor DNA (ctDNA) in resected pancreatic ductal adenocarcinoma: A systematic review and meta-analysis.
49. Comparative molecular profiling of pancreatic ductal adenocarcinoma (PDAC) of the head (H) versus body/tail (B/T) and the tumor immune microenvironment (TIME).
50. LRP1B and GRM3 expression in colorectal cancer.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.